KIF18A-IN-12, with the CAS number 3033980-95-6, is a small molecule inhibitor that targets the kinesin motor protein KIF18A, which plays a crucial role in mitotic spindle assembly and chromosome alignment during cell division. This compound is part of a broader class of inhibitors that are being investigated for their potential in cancer therapy, particularly in disrupting the mitotic process in rapidly dividing cancer cells. KIF18A-IN-12 is characterized by its ability to interfere with the normal function of KIF18A, thereby inducing mitotic defects and potentially leading to apoptosis in tumor cells. The compound's structure typically includes specific functional groups that enhance its binding affinity to the target protein, although detailed structural information is often proprietary. Research into KIF18A-IN-12 is ongoing, focusing on its efficacy, selectivity, and pharmacokinetic properties, which are essential for its development as a therapeutic agent. As with many experimental compounds, further studies are needed to fully understand its biological effects and potential clinical applications.

KIF18A-IN-12

3033980-95-6: KIF18A-IN-12, with the CAS number 3033980-95-6, is a small molecule inhibitor that targets the kinesin motor protein KIF18A, which plays a crucial role in mitotic spindle assembly and chromosome alignment during cell division. This compound is part of a broader class of inhibitors that are being investigated for their potential in cancer therapy, particularly in disrupting the mitotic process in rapidly dividing cancer cells. KIF18A-IN-12 is characterized by its ability to interfere with the normal function of KIF18A, thereby inducing mitotic defects and potentially leading to apoptosis in tumor cells. The compound's structure typically includes specific functional groups that enhance its binding affinity to the target protein, although detailed structural information is often proprietary. Research into KIF18A-IN-12 is ongoing, focusing on its efficacy, selectivity, and pharmacokinetic properties, which are essential for its development as a therapeutic agent. As with many experimental compounds, further studies are needed to fully understand its biological effects and potential clinical applications.

<p>KIF18A-IN-12 (compound 9), a potent KIF18A inhibitor, exhibits an IC 50 of 45.54 nM and is utilized in cancer research.</p>

CAS 3033980-95-6

KIF18A-IN-12

KIF18A-IN-12

Ref: TM-T88046